Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
NCT06586281 · Psoriatic Arthritis
RecruitingWhile many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.
PhaseNA
TypeInterventional
AgeAny
WhereSan Diego, California, United States
SponsorUniversity of California, San Diego
▾Tap for detailsClick for full details — eligibility, all locations, contacts Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects
RecruitingRandomized, controlled trial, Proof of Concept, Phase 2 aimed to evaluate the effect of CBP-0276 in dose of 200mg twice dose a day, or placebo administrated for 36 weeks to improve Psoriasis Area and Severity Index (PASI)75 or static Physician's Global Assessment (sPGA) score of 0 or 1; PASI50, PASI90, PASI100, Scalp-specific Physician's Global Assessment (Ss-PGA) 0/1 with at least a 2-point improvement among patients with a baseline ss-PGA ≥3, sPGA 0, PSSD symptom score of 0 among patients with baseline score ≥1, Dermatology Life Quality Index (DLQI) 0/1 at Week 6,12,18,24, 30 and 36 among patients with baseline DLQI ≥2, adjusted by transcriptomics profile (post-hoc analysis), Percentage of subjects which achieve The Minimum Clinically Important Difference (MCID) on DLQI (a ≥4-point reduction from baseline) at Week 4 and 8, Frequency of solicited and unsolicited adverse events (SAEs and USAEs) (Medra), and Changes on inflammatory and anti-inflammatory cytokine levels during treatment (IL-17, IL-23, IL-6, TNF-alpha, IL1-b, IL-10).
PhasePhase 2
TypeInterventional
Age18 Years – 70 Years
WhereMexico City, Mexico
SponsorClarent Biopharma, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts PsoBest - The German Psoriasis Registry
NCT01848028 ·
Psoriasis, Psoriatic-arthritis
RecruitingTreatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.
Phase—
TypeObservational
Age18 Years
WhereHamburg, Germany
SponsorUniversitätsklinikum Hamburg-Eppendorf
▾Tap for detailsClick for full details — eligibility, all locations, contacts The Norwegian Antirheumatic Drug Register
NCT01581294 · Inflammatory Joint Diseases
RecruitingNOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.
Phase—
TypeObservational
Age18 Years
WhereDrammen, Buskerud, Norway + 5 more
SponsorDiakonhjemmet Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Deployment o the Multidisciplinary Prospective Cohort Imminent
NCT04334031 · Chronic Inflammatory Disease, Angioedema,
Severe Asthma RecruitingImmune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment. These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.
PhaseNA
TypeInterventional
Age18 Years
WhereLille, France
SponsorUniversity Hospital, Lille
▾Tap for detailsClick for full details — eligibility, all locations, contacts Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
RecruitingPsoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact, disability and work productivity of affected individuals. PsO is associated with an increased risk of cardiovascular morbidities and mortality in the long term. Up to 30% of PsO patients develop psoriatic arthritis (PsA) over time causing joint deformities and further disabilities. Majority of patients with PsA developed PsO first, and arthritis develop 5-10 years afterwards. PsA and PsO are increasingly recognized as two entities under the umbrella of psoriatic diseases. Advances in biological treatments have greatly improved the prognosis of patients with PsO. Remarkable efficacies have been demonstrated for patients with moderate to severe PsO in randomized controlled trials (RCTs). However, the high cost of biological treatment is one of the major barriers to prescription of biological treatment and many patients may have limited access to these treatments. The best strategy of treatment for PsO that takes into account efficacy and cost effectiveness is unknown. For instance, whether some PsO patients can stop biological treatment and be retreated with non-biologic medications upon relapse, which may enhance cost effectiveness of treatment. Preliminary studies have shown that some PsO patients were able to maintain good control of disease without medications after biologics withdrawal. The patho-immunological mechanisms behind long term remission after drug withdrawal is poorly understood. Better understanding on patho-immunological mechanisms on maintenance of remission and relapses will advance the development of biomarkers that eventually guide development of best treatment strategies for PsO. Ixekizumab is a humanized immunoglobulin G4 (IgG4 kappa) monoclonal antibody targeting interleukin (IL)-17A. It is highly efficacious in the treatment of plague PsO with and favorable safety profile as shown in randomized controlled trials, and is an approved treatment for moderate-to-severe PsO by the U.S. Food and Drug Administration and Health Sciences Authority. With the proven efficacies, ixekizumab could be a choice of first-line treatment for patients with moderate to severe PsO. The 2013 American Academy of Dermatology position statement have stated that the old paradigm of stepwise-therapy starting first with phototherapy and oral systemic therapies before biologic treatment is not required for patients with moderate to severe PsO. In the recent 2017 update of the European S3 guidelines also recommend the use of IL-17 inhibitors as either a first- or second-line agent. In a RCT that evaluated relapses after withdrawal of ixekizumab among patients who achieved a clearance of PsO, loss of PsO clearance were seen after a median of 20 weeks. Response can be successfully recaptured in over 80% of patients with retreatment with ixekizumab, suggesting that the treatment regimen could be interrupted in some patients. However, real-life data on biologic treatment or withdrawal for moderate to severe PsO is scatty.
PhasePhase 4
TypeInterventional
Age22 Years – 90 Years
WhereOutram Park, Singapore
SponsorSingapore General Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
NCT07280702 · Psoriatic Arthritis (PsA)
RecruitingThe purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
PhasePhase 4
TypeInterventional
Age18 Years – 65 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
RecruitingThe purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
PhasePhase 2
TypeInterventional
Age18 Years
WhereBeijing, Beijng, China
SponsorHansoh BioMedical R&D Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
NCT07038720 ·
Plaque Psoriasis, Healthy Volunteer
RecruitingThis study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets. The study consists of four parts: Part A is a single ascending dose (SAD) study, Part B is a multiple ascending dose (MAD) study, Part C is a food effect (FE) study, and Part D is a multi-dose parallel control study. Part A, B, and C will be conducted in healthy subject, and Part D will be conducted in subjects with moderate to severe plaque psoriasis.
PhasePhase 1
TypeInterventional
Age18 Years – 55 Years
WhereHangzhou, Zhejiang, China
SponsorUsynova Pharmaceuticals Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RecruitingA study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
PhasePhase 3
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 410 more
SponsorBristol-Myers Squibb
▾Tap for detailsClick for full details — eligibility, all locations, contacts Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control
RecruitingYour research study is about evaluating the effectiveness of \*\*Mindfulness-Based Cognitive Therapy (MBCT)\*\* in reducing psychological distress among psoriasis patients and improving their self-compassion and Mental Health Locus of Control (MHLC). The study highlights that psoriasis patients often suffer not only from physical symptoms but also from psychological problems such as stress, anxiety, depression, self-judgment, and low self-compassion. Traditional treatments mainly focus on physical symptoms and may not fully address these emotional and psychological difficulties. To address this gap, the study proposes MBCT as a psychological intervention that combines mindfulness practices with cognitive therapy techniques. MBCT helps patients become more self-aware, reduce negative thinking, and develop self-compassion without self-judgment. The research also explores MHLC, which refers to how much control individuals believe they have over their health outcomes. The study aims to investigate whether MBCT can: * Reduce psychological distress, anxiety, depression, and stress levels * Improve self-compassion among psoriasis patients * Shift patients' locus of control from external to internal * Enhance emotional well-being and coping mechanisms The research follows a quantitative experimental design conducted in phases. Initially, baseline levels of distress, MHLC, and self-compassion will be assessed. Later, MBCT interventions will be implemented and evaluated for effectiveness. Overall, the study seeks to contribute to integrated psoriasis care by emphasizing the importance of psychological health alongside physical treatment, ultimately improving patients' quality of life and therapeutic outcomes.
PhaseNA
TypeInterventional
Age25 Years – 75 Years
WhereRahim Yar Khan, Punjab Province, Pakistan
SponsorIslamia University of Bahawalpur
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
NCT07850310 ·
Psoriasis, Healthy
RecruitingThe purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people. This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.
PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WhereMelbourne, Victoria, Australia
SponsorMerck Sharp & Dohme LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT07406035 · Psoriatic Arthritis
RecruitingThis study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.
PhasePhase 2
TypeInterventional
Age18 Years – 70 Years
WhereBozhou, Anhui, China + 43 more
SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts SEquential Treatment of PSoriasis With Biologics
RecruitingPsoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases. This study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required
Phase—
TypeObservational
Age18 Years
WhereBath, Somerset, United Kingdom
SponsorRoyal United Hospitals Bath NHS Foundation Trust
▾Tap for detailsClick for full details — eligibility, all locations, contacts Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RecruitingThe investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.
PhasePhase 4
TypeInterventional
Age18 Years – 89 Years
WhereCleveland, Ohio, United States
SponsorUniversity Hospitals Cleveland Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
RecruitingThe goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug). Participants will: * Take Viv or a placebo every day for 3 months. * Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months. * Be provided with at home blood collection kits, which they will use to collect blood at the beginning of the study and again at 1 months and 3 months. Researchers will analyze these blood samples to measure the levels of specific inflammatory proteins and evaluate how they change over the course of the study in the participants taking Viv compared to those taking placebo.
PhaseNA
TypeInterventional
Age18 Years
WhereEnglewood, New Jersey, United States
SponsorSirt3 LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts Modifying PEST for Psoriatic Arthritis Screening
NCT06382051 ·
Plaque Psoriasis, Psoriatic Arthritis
RecruitingThe purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
PhaseNA
TypeInterventional
Age18 Years
WhereCalgary, Alberta, Canada + 29 more
SponsorNovartis Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT07401992 ·
Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2
RecruitingThis study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.
PhasePhase 4
TypeInterventional
Age18 Years
WhereMonterrey, N.L., Mexico
SponsorHospital Universitario Dr. Jose E. Gonzalez
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420 · Palmoplantar Pustulosis
RecruitingThe purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 90 more
SponsorUCB Biopharma SRL
▾Tap for detailsClick for full details — eligibility, all locations, contacts Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RecruitingThe purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
PhasePhase 1
TypeInterventional
Age18 Years
WherePompano Beach, Florida, United States + 2 more
SponsorSFA Therapeutics
▾Tap for detailsClick for full details — eligibility, all locations, contacts